Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2009

01.08.2009 | Preclinical Study

Glucocorticoid receptor expression in breast cancer associates with older patient age

verfasst von: Larissa Belova, Bertha Delgado, Masha Kocherginsky, Amal Melhem, Olufunmilayo I. Olopade, Suzanne D. Conzen

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer can be classified according to estrogen (ER), progesterone (PR), and HER2 receptor expression. Recent evidence suggests that activation of the glucocorticoid receptor (GR) contributes to breast cell survival, although the incidence of GR expression in primary human breast tumors is not well established. We therefore evaluated ER, PR, HER2, and GR by immunohistochemistry from 231 patients and found that while African American (AA) patient tumors were much more likely to be ER negative compared to tumors from non-AA patients, GR expression was significantly higher in tumors from patients ≥50 regardless of ancestry. Prospective examination of GR expression in tumors should be considered to determine whether GR contributes to long-term clinical outcome.
Literatur
1.
Zurück zum Zitat Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM, Kuo YH et al (2006) Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol 209(3):317–327. doi:10.1002/path.1982 PubMedCrossRef Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM, Kuo YH et al (2006) Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol 209(3):317–327. doi:10.​1002/​path.​1982 PubMedCrossRef
2.
Zurück zum Zitat Conde I, Paniagua R, Fraile B, Lucio J, Arenas MI (2008) Glucocorticoid receptor changes its cellular location with breast cancer development. Histol Histopathol 23(1):77–85PubMed Conde I, Paniagua R, Fraile B, Lucio J, Arenas MI (2008) Glucocorticoid receptor changes its cellular location with breast cancer development. Histol Histopathol 23(1):77–85PubMed
5.
Zurück zum Zitat Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD (2006) Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 5(8):933–940PubMedCrossRef Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD (2006) Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 5(8):933–940PubMedCrossRef
7.
Zurück zum Zitat Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64(5):1757–1764. doi:10.1158/0008-5472.CAN-03-2546 PubMedCrossRef Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64(5):1757–1764. doi:10.​1158/​0008-5472.​CAN-03-2546 PubMedCrossRef
8.
Zurück zum Zitat Bamberger CM, Schulte HM, Chrousos GP (1996) Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 17(3):245–261. doi:10.1210/er.17.3.245 PubMed Bamberger CM, Schulte HM, Chrousos GP (1996) Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 17(3):245–261. doi:10.​1210/​er.​17.​3.​245 PubMed
9.
Zurück zum Zitat Brewer JA, Vogt SK, Sleckman BP, Swat W, Kanagawa O, Muglia LJ (2002) Knock-ins and conditional knockouts: in vivo analysis of glucocorticoid receptor regulation and function. Endocr Res 28(4):545–550. doi:10.1081/ERC-120016839 PubMedCrossRef Brewer JA, Vogt SK, Sleckman BP, Swat W, Kanagawa O, Muglia LJ (2002) Knock-ins and conditional knockouts: in vivo analysis of glucocorticoid receptor regulation and function. Endocr Res 28(4):545–550. doi:10.​1081/​ERC-120016839 PubMedCrossRef
11.
Zurück zum Zitat Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML et al (2006) Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer 53(3):303–310. doi:10.1016/j.lungcan.2006.05.005 PubMedCrossRef Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML et al (2006) Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer 53(3):303–310. doi:10.​1016/​j.​lungcan.​2006.​05.​005 PubMedCrossRef
12.
Zurück zum Zitat Rajatapiti P, Kester MH, de Krijger RR, Rottier R, Visser TJ, Tibboel D (2005) Expression of glucocorticoid, retinoid, and thyroid hormone receptors during human lung development. J Clin Endocrinol Metab 90(7):4309–4314. doi:10.1210/jc.2005-0556 PubMedCrossRef Rajatapiti P, Kester MH, de Krijger RR, Rottier R, Visser TJ, Tibboel D (2005) Expression of glucocorticoid, retinoid, and thyroid hormone receptors during human lung development. J Clin Endocrinol Metab 90(7):4309–4314. doi:10.​1210/​jc.​2005-0556 PubMedCrossRef
13.
Zurück zum Zitat Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 276(20):16649–16654. doi:10.1074/jbc.M010842200 PubMedCrossRef Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 276(20):16649–16654. doi:10.​1074/​jbc.​M010842200 PubMedCrossRef
15.
Zurück zum Zitat Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH et al (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 143(1):109–118. doi:10.1016/j.jss.2007.03.085 PubMedCrossRef Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH et al (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 143(1):109–118. doi:10.​1016/​j.​jss.​2007.​03.​085 PubMedCrossRef
16.
Zurück zum Zitat Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A (1997) Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 70(6):639–643. doi :10.1002/(SICI)1097-0215(19970317)70:6<639::AID-IJC2<3.0.CO;2-WPubMedCrossRef Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A (1997) Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 70(6):639–643. doi :10.1002/(SICI)1097-0215(19970317)70:6<639::AID-IJC2<3.0.CO;2-WPubMedCrossRef
17.
Zurück zum Zitat Purmonen S, Manninen T, Pennanen P, Ylikomi T (2008) Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep 19(6):1627–1634PubMed Purmonen S, Manninen T, Pennanen P, Ylikomi T (2008) Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep 19(6):1627–1634PubMed
20.
Zurück zum Zitat Hall RE, Lee CS, Alexander IE, Shine J, Clarke CL, Sutherland RL (1990) Steroid hormone receptor gene expression in human breast cancer cells: inverse relationship between oestrogen and glucocorticoid receptor messenger RNA levels. Int J Cancer 46(6):1081–1087. doi:10.1002/ijc.2910460622 PubMedCrossRef Hall RE, Lee CS, Alexander IE, Shine J, Clarke CL, Sutherland RL (1990) Steroid hormone receptor gene expression in human breast cancer cells: inverse relationship between oestrogen and glucocorticoid receptor messenger RNA levels. Int J Cancer 46(6):1081–1087. doi:10.​1002/​ijc.​2910460622 PubMedCrossRef
21.
23.
26.
Zurück zum Zitat Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW et al (2008) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat; Epub ahead of print Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW et al (2008) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat; Epub ahead of print
28.
Zurück zum Zitat Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23PubMed Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23PubMed
Metadaten
Titel
Glucocorticoid receptor expression in breast cancer associates with older patient age
verfasst von
Larissa Belova
Bertha Delgado
Masha Kocherginsky
Amal Melhem
Olufunmilayo I. Olopade
Suzanne D. Conzen
Publikationsdatum
01.08.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0136-9

Weitere Artikel der Ausgabe 3/2009

Breast Cancer Research and Treatment 3/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.